- Report
- September 2026
- 181 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- September 2026
- 196 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- January 2026
- 185 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- November 2026
- 197 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 82 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- May 2026
- 250 Pages
Global
From €4230EUR$4,490USD£3,522GBP
- Report
- February 2026
- 250 Pages
Global
From €4230EUR$4,490USD£3,522GBP
- Report
- February 2026
- 250 Pages
Global
From €4230EUR$4,490USD£3,522GBP
- Report
- February 2026
- 250 Pages
Global
From €4230EUR$4,490USD£3,522GBP
- Report
- February 2026
- 250 Pages
Global
From €4230EUR$4,490USD£3,522GBP
- Report
- February 2026
- 250 Pages
Global
From €4230EUR$4,490USD£3,522GBP
- Report
- February 2026
- 250 Pages
Global
From €4230EUR$4,490USD£3,522GBP
- Report
- September 2026
- 200 Pages
Global
From €7528EUR$7,990USD£6,268GBP
- Report
- August 2020
- 250 Pages
Saudi Arabia
From €3392EUR$3,600USD£2,824GBP
- Report
- March 2024
- 200 Pages
Global
From €3910EUR$4,150USD£3,255GBP
- Report
- January 2024
- 200 Pages
Global
From €3910EUR$4,150USD£3,255GBP
- Report
- August 2026
- 180 Pages
From €4475EUR$4,750USD£3,726GBP
- Report
- August 2026
- 70 Pages
India
From €4475EUR$4,750USD£3,726GBP
- Report
- August 2026
- 70 Pages
Malaysia
From €4475EUR$4,750USD£3,726GBP
- Report
- August 2026
- 70 Pages
Vietnam
From €4475EUR$4,750USD£3,726GBP

Sitagliptin is a drug used to treat endocrine and metabolic disorders. It is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which works by increasing the levels of incretin hormones in the body. These hormones help to regulate glucose levels in the blood, and can help to reduce the risk of developing type 2 diabetes. Sitagliptin is usually prescribed in combination with other drugs, such as metformin, to help control blood sugar levels. It is also used to treat other conditions, such as polycystic ovary syndrome and non-alcoholic fatty liver disease.
Sitagliptin is available in both oral and injectable forms, and is generally well tolerated with few side effects. It is a relatively new drug, and is becoming increasingly popular as a treatment for endocrine and metabolic disorders.
Some companies in the Sitagliptin market include Merck & Co., Inc., Novartis AG, and Takeda Pharmaceutical Company Limited. Show Less Read more